Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
202.47(c) 199.19(c) 208.24(c) 221.36(c) 212.04(c) Last
4 955 160 6 663 813 7 423 063 10 066 344 14 506 327 Volume
+2.34% -1.62% +4.54% +6.30% -4.21% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 18 632 M - -
Net income 2021 10 719 M - -
Net cash position 2021 11 520 M - -
P/E ratio 2021 8,60x
Yield 2021 -
Sales 2022 15 883 M - -
Net income 2022 7 395 M - -
Net cash position 2022 20 906 M - -
P/E ratio 2022 12,0x
Yield 2022 -
Capitalization 85 140 M 85 140 M -
EV / Sales 2021 3,95x
EV / Sales 2022 4,04x
Nbr of Employees 1 300
Free-Float 90,3%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and... 
More about the company
Ratings of Moderna, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about MODERNA, INC.
05:22pMODERNA  : Canadian co-founder of Moderna wins science award for mRNA research
AQ
04:54pUS Stocks End Mixed, Nasdaq Hits Intraday High on Tesla Rally
MT
04:45pCLOSE UPDATE : US Stocks End Mixed, Nasdaq Hits Intraday High on Tesla Rally
MT
04:22pTHE LATEST : Israel delays reopening of borders to tourists
AQ
03:51pMODERNA  : U.S. CDC Says Administered 319,872,053 Doses Of Covid-19 Vaccine As O..
RE
03:12pMODERNA  : NIH begins clinical trial testing COVID-19 vaccine in pregnant women
RE
01:19pStocks Mixed Midday as Defensives Trade Lower; Oil Advances as Crude Stockpil..
MT
01:04pMIDDAY REPORT : US Stocks Mixed as Defensives Trade Lower; Oil Advances as Crude..
MT
12:02pMODERNA  : 'Likely link' between rare heart inflammation and Pfizer, Moderna vac..
RE
11:49aUS' CDC To Study Possible Link Between Heart Inflammation And Pfizer/BioNTech..
MT
10:39aGSK's drugs arm to get $11 billion booster from consumer spin-off
RE
10:17aMODERNA  : European Commission Purchases Additional 150 Million Doses of Moderna..
AQ
08:58aMODERNA  : Japan to halt company applications for workplace vaccinations
AQ
08:23aMODERNA  : CureVac founder withdraws candidacy for supervisory board
AQ
06:01aTHE LATEST : COVID-19 cluster worsens in Australian city
AQ
More news
News in other languages on MODERNA, INC.
05:11pCORONAVIRUS : un comité US se penche sur des problèmes cardiaques chez des jeune..
01:13pCORONA-BLOG/WHO stellt Mängel in Produktionsstätte für russischen Impfstoff f..
11:58aCORONA-BLOG/BEHÖRDE  : Delta-Variante könnte bald für 90% der Fälle in EU verant..
11:36aCORONA-BLOG/Delta-Variante breitet sich in Frankreich aus
11:35aCORONA-BLOG/Spahn warnt vor "Sorgenherbst" nach der Urlaubssaison
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 2020
The beginning of the move
BUY
More Stock Trading Analysis
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 212,04 $
Average target price 168,87 $
Spread / Average Target -20,4%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.102.97%88 882
LONZA GROUP AG14.06%52 367
IQVIA HOLDINGS INC.36.17%46 761
CELLTRION, INC.-21.59%32 903
SEAGEN INC.-9.40%28 797
HANGZHOU TIGERMED CONSULTING CO., LTD20.45%25 469